Status:
COMPLETED
Effectivity and Safety of Different Anticoagulants in Patients With Thromboembolic Antiphospholipid Syndrome
Lead Sponsor:
Cardioangiologisches Centrum Bethanien
Conditions:
Antiphospholipid Syndrome
Venous Thromboembolism
Eligibility:
All Genders
18-100 years
Brief Summary
Retrospective monocentric registry to evaluate the efficacy and safety of different anticoagulants in patients with thromboembolic antiphospholipid syndrome
Detailed Description
Antiphospholipid syndrome is a thrombophilic diathesis characterised by the occurrence of recurrent, unprovoked thromboembolic events (arterial, venous, microvascular) in combination with the presence...
Eligibility Criteria
Inclusion
- Minimum age of 18 years
- Confirmed antiphospholipid syndrome with thromboembolic clinical manifestations (VTE, LAE, stroke etc.)
- Patients with APS antibody risk profile (single/double/triple positivity)
Exclusion
- APS with isolated pregnancy complications
- No coagulation inhibition
- Inadequately diagnosed APS
- Non-compliance of patients
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05195372
Start Date
January 1 2015
End Date
July 1 2022
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Edelgard Lindhoff-Last
Frankfurt am Main, Hesse, Germany, 60389